References

vsp

Вопросы современной педиатрии

Current Pediatrics

1682-55271682-5535

Издательство «ПедиатрЪ»

10.15690/vsp.v14i2.1289

vsp-61

Research Article

ОБЗОРЫ ЛИТЕРАТУРЫ

LITERATURE REVIEW

ПРОДУКТЫ МЕТАБОЛИЗМА КИШЕЧНОЙ МИКРОФЛОРЫ: ВОЗМОЖНА ЛИ ИЗБИРАТЕЛЬНАЯ КОРРЕКЦИЯ?

PRODUCTS OF METABOLISM OF THE INTESTINAL MICROFLORA: CAN WE USE THE SELECTIVE CORRECTION?

Хавкин

А. И.

Khavkin

A. I.

доктор медицинских наук, профессор, заведующий отделом гастроэнтерологии НИКИ педиатрии РНИМУ им. Н.И. Пирогова Адрес: 125412, Москва, ул. Талдомская, д. 2, тел.: +7 (499) 487-46-81

akhavkin@pedklin.ru

Комарова

О. Н.

Komarova

O. N.

akhavkin@pedklin.ru

Российский научно-исследовательский медицинский университет им. Н.И. Пирогова, Москва, Российская ФедерацияРоссияN.I. Pirogov Russian National Research Medical University, Moscow, Russian FederationRussian Federation

2015

17042015

142

Вопросы современной педиатрии

212218

2015

Хавкин А.И., Комарова О.Н.

Khavkin A.I., Komarova O.N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://vsp.spr-journal.ru/jour/article/view/61

Нарушение количественных и качественных характеристик кишечной микробиоты — одна из причин развития широкого спектра патологических состояний в любой возрастной группе. С целью коррекции подобных нарушений используют пробиотики (препараты активной микрофлоры) и пребиотики (олигосахариды, способствующие росту позитивной флоры). Перспективно применение и метаболических пребиотиков — экстрактов продуктов обмена веществ позитивной флоры, которые, подобно олигосахаридным пребиотикам, стимулируют рост микробиоты. Сравнительный анализ метаболома некоторых представителей кишечной микрофлоры и препаратов, содержащих продукты обмена бактерий, позволяет понять механизмы их терапевтического воздействия, открывает перспективы разработки комплексного воздействия при использовании с витаминами В6, В2, каротиноидами, селеном, глутатионом. Результаты метаболомного анализа дают возможнось утверждать, что метаболиты таких представителей микрофлоры, как Escherichia coli, Streptococcus faecalis, Lactobacillus acidophilus, Lactobacillus helveticus, способствуют выживанию позитивной флоры и в то же время могут тормозить рост патогенной микрофлоры.

Disturbed quantitative and qualitative characteristics of the intestinal microbiota are one of the reasons for the development of a wide range of pathological conditions in any age group. To correct these disorders, probiotics (active microflora drugs) and prebiotics (oligosaccharides that promote the growth of positive flora) are used. The use of metabolic prebiotics is also promising. Metabolic prebiotics are extracts of metabolic products of positive flora that, like the oligosaccharide prebiotics, stimulate the growth of the microbiota. Comparative analysis of the metabolome of some representatives of the intestinal microflora and preparations containing metabolic products of bacteria explains the mechanisms of their therapeutic effects and opens up prospects for the development of integrated treatment with the use of vitamins B6, B2, carotenoids, selenium, and glutathione. The results of the metabolome analysis suggest that the metabolites of the microflora representatives such as Escherichia coli, Streptococcus faecalis, Lactobacillus acidophilus, and Lactobacillus helveticus promote the survival of positive flora and at the same time can inhibit the growth of pathogenic microflora.

микробиотамикрофлораметаболомдисбактериозпробиотикипребиотики

microbiotamicroflorametabolomedysbacteriosisprobioticsprebiotics

References1

Moore W. E., Holdeman L. V. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl. Microbiol. 1974; 27: 961–979.

Moore W.E., Holdeman L.V. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl. Microbiol. 1974; 27: 961–979.

Noack J., Kleessen B., Proll J., Dongowski G., Blaut M. Dietary guar gum and pectin stimulate intestinal microbial polyamine synthesis in rats. J. Nutr. 1998; 128: 1385–1391.

Khavkin A.I. Mikroflora pishchevaritel'nogo trakta [Microflora of the Digestive System]. Moscow, Fond sotsial'noi pediatrii, 2006. 416 p.

Ursova N.I. Disbakteriozy kishechnika v detskom vozraste: innovatsii v diagnostike, korrektsii i profilaktike [Intestinal Dysbiosis in Children: Innovations in the Diagnosis, Prevention and Correction]. Moscow, 2013. 328 p.

Limanova O.A., Fedotova L.E., Sadin A.V. Klinicheskaya farmakologiya preparatov, primenyaemykh dlya lecheniya disbakterioza kishechnika [Clinical Pharmacology of Drugs used for Treatment of Intestinal Dysbiosis]. Ivanovo, 2007. 23 p.

Kilkkinen A., Pietinen P., Klaukka T., Virtamo J., Korhonen P., Adlercreutz H. Use of oral antimicrobials decreases serum enterolactone concentration. Am. J. Epidemiol. 2002; 155: 472–477.

Hurley B. W., Nguyen C. C. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch. Intern. Med. 2002; 162: 2177–2184.

Hurley B.W., Nguyen C.C. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch. Intern. Med. 2002; 162: 2177–2184.

Macfarlane G. T., Gibson G. R. Metabolic activities of the normal colonic flora. In: Human Health: The Contribution of Microorganisms. S. A. W. Gibson (ed.). London: Springer-Verlag. 1994. P. 17–53.

Macfarlane G.T., Gibson G.R. Metabolic activities of the normal colonic flora. In: Human Health: The Contribution of Microorganisms. S.A.W. Gibson (ed.). London: Springer-Verlag. 1994. P. 17–53.

Macfarlane S., Macfarlane G. T. Proteolysis and amino acid fermentation. In: Human Colonic Bacteria: Role in Nutrition, Physiology, and Pathology. G. R. Gibson, G. T. Macfarlane (eds.). Boca Raton, FL: CRC Press. 1995. P. 75–100.

Macfarlane S., Macfarlane G.T. Proteolysis and amino acid fermentation. In: Human Colonic Bacteria: Role in Nutrition, Physiology, and Pathology. G.R. Gibson, G.T. Macfarlane (eds.). Boca Raton, FL: CRC Press. 1995. P. 75–100.

Kruis W., Forstmaier G., Scheurlen C., Stellaard F. Effect of diets low and high in refined sugars on gut transit, bile acid metabolism, and bacterial fermentation. Gut. 1991; 32: 367–371.

WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria (October 2001). «Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria». Food and Agriculture Organization of the United Nations, World Health Organization. http://www.who.int/ foodsafety/publications/fs_management/en/probiotics.pdf (available: 07.03.2015).

WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria (October 2001). «Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria». Food and Agriculture Organization of the United Nations, World Health Organization. http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf (available: 07.03.2015).

Metchnikov I. Essais optimistes. Paris. 1907. 438 p.

Roberfroid M. Prebiotics: the concept revisited. J. Nutr. 2007; 137 (Suppl. 3): 830–837.

Tabolin V.A., Bel'mer S.V., Gasilina T.V., Mukhina Yu.G., Korneva T.I. Ratsional'naya terapiya disbakterioza kishechnika u detei. Metod. rekomendats [Rational Treatment of Intestinal Dysbiosis in Children. Method. recommendations]. Moscow, 1998. 24 p.

Biville F., Laurent-Winter C., Danchin A. In vivo positive effects of exogenous pyrophosphate on Escherichia coli cell growth and stationary phase survival. Res. Microbiol. 1996; 147 (8): 597–608.

Gritsenko V. A., Brudastov Iu. A., Kudria E. V., Vasil'eva L. I. Comparative analysis of the sensitivity of enterobacteria to bile. Zh. Mikrobiol. Epidemiol. Immunobiol. 2002; 3: 65–67.

Gritsenko V.A., Brudastov Iu.A., Kudria E.V., Vasil'eva L.I. Comparative analysis of the sensitivity of enterobacteria to bile. Zh. Mikrobiol. Epidemiol. Immunobiol. 2002; 3: 65–67.

Kyriakidis D. A., Tiligada E. Signal transduction and adaptive regulation through bacterial two-component systems: the Escherichia coli AtoSC paradigm. Amino Acids. 2009; 37 (3): 443.

Kyriakidis D.A., Tiligada E. Signal transduction and adaptive regulation through bacterial two-component systems: the Escherichia coli AtoSC paradigm. Amino Acids. 2009; 37 (3): 443.

Hori Y., Nihei Y., Kurokawa Y., Kuramasu A., Makabe-Kobayashi Y., Terui T., Doi H., Satomi S., Sakurai E., Nagy A., Wata nabe T., Ohtsu H. Accelerated clearance of Escherichia coli in experi mental peritonitis of histamine-deficient mice. J. Immunol. 2002; 169 (4): 1978–1983.

Hori Y., Nihei Y., Kurokawa Y., Kuramasu A., Makabe-Kobayashi Y., Terui T., Doi H., Satomi S., Sakurai E., Nagy A., Watanabe T., Ohtsu H. Accelerated clearance of Escherichia coli in experimental peritonitis of histamine-deficient mice. J. Immunol. 2002; 169 (4): 1978–1983.

Bailey M. T., Coe C. L. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev. Psychobiol. 1999; 35: 146–155.

Bailey M.T., Coe C.L. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev. Psychobiol. 1999; 35: 146–155.

Lyte M., Ernst S. Catecholamine induced growth of gram negative bacteria. Life Sci. 1992; 50: 203–212.

Hall-Stoodley L., Costerton J. W., Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2004; 2 (2): 95–108.

Hall-Stoodley L., Costerton J.W., Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2004; 2 (2): 95–108.

Bukharin O. V., Petrunova N. B. Microbial «friend-foe» identifi-ca tion in human intestine microsymbiocenosis. Zh. Mikrobiol. Epidemiol. Immunobiol. 2011; 6: 46–51.

Bukharin O.V., Petrunova N.B. Microbial «friend-foe» identification in human intestine microsymbiocenosis. Zh. Mikrobiol. Epidemiol. Immunobiol. 2011; 6: 46–51.

Yates E. A., Philipp B., Buckley C., Atkinson S., Chhabra S. R., Sockett R. E., Goldner M., Dessaux Y., Camara M., Smith H., Williams P. N-acylhomoserine lactones undergo lactonolysis in a pH-, temperature-, and acyl chain length-dependent manner during growth of Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Infect. Immun. 2002; 70 (10): 5635–5646.

Yates E.A., Philipp B., Buckley C., Atkinson S., Chhabra S.R., Sockett R.E., Goldner M., Dessaux Y., Camara M., Smith H., Williams P. N-acylhomoserine lactones undergo lactonolysis in a pH-, temperature-, and acyl chain length-dependent manner during growth of Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Infect. Immun. 2002; 70 (10): 5635–5646.

Wang X. D., de Boer P. A., Rothfield L. I. A factor that positively regulates cell division by activating transcription of the major cluster of essential cell division genes of Escherichia coli. EMBO J. 1991; 10 (11): 3363–3372.

Wang X.D., de Boer P.A., Rothfield L.I. A factor that positively regulates cell division by activating transcription of the major cluster of essential cell division genes of Escherichia coli. EMBO J. 1991; 10 (11): 3363–3372.

Qazi S., Middleton B., Muharram S. H., Cockayne A., Hill P., O'Shea P., Chhabra S. R., Camara M., Williams P. N-acylhomoserine lactones antagonize virulence gene expression and quorum sensing in Staphylococcus aureus. Infect. Immun. 2006; 74 (2): 910–919.

Qazi S., Middleton B., Muharram S.H., Cockayne A., Hill P., O'Shea P., Chhabra S.R., Camara M., Williams P. N-acylhomoserine lactones antagonize virulence gene expression and quorum sensing in Staphylococcus aureus. Infect. Immun. 2006; 74 (2): 910–919.

Hall R. A., Turner K. J., Chaloupka J., Cottier F., De Sordi L., Sanglard D., Levin L. R., Buck J., Muhlschlegel F. A. The quorum-sensing molecules farnesol/homoserine lactone and dodecanol operate via distinct modes of action in Candida albicans. Eukaryot. Cell. 2011; 10 (8): 1034–1042.

Hall R.A., Turner K.J., Chaloupka J., Cottier F., De Sordi L., Sanglard D., Levin L.R., Buck J., Muhlschlegel F.A. The quorum-sensing molecules farnesol / homoserine lactone and dodecanol operate via distinct modes of action in Candida albicans. Eukaryot. Cell. 2011; 10 (8): 1034–1042.

Miller M. B., Bassler B. L. Quorum sensing in bacteria. Ann. Rev. Microbiol. 2001; 55: 165–199.

Miller M.B., Bassler B.L. Quorum sensing in bacteria. Ann. Rev. Microbiol. 2001; 55: 165–199.

Diggle S. P., Gardner A., West S. A., Griffin A. S. Evolutionary theory of bacterial quorum sensing: when is a signal not a signal? Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2007; 362 (1483): 1241–1249.

Diggle S.P., Gardner A., West S.A., Griffin A.S. Evolutionary theory of bacterial quorum sensing: when is a signal not a signal? Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2007; 362 (1483): 1241–1249.

Lyte M., Frank C. D., Green B. T. Production of an autoinducer of growth by norepinephrine cultured Escherichia coli 0157: H7. FEMS Microbiol. Lett. 1996; 139: 155–159.

Lyte M., Frank C.D., Green B.T. Production of an autoinducer of growth by norepinephrine cultured Escherichia coli 0157:H7. FEMS Microbiol. Lett. 1996; 139: 155–159.

Shimazaki J., Furukawa S., Ogihara H., Morinaga Y. L-Tryptophan pre vents Escherichia coli biofilm formation and triggers biofilm degra dation. Biochem. Biophys. Res. Commun. 2012; 419 (4): 715–718.

Shimazaki J., Furukawa S., Ogihara H., Morinaga Y. L-Tryptophan prevents Escherichia coli biofilm formation and triggers biofilm degradation. Biochem. Biophys. Res. Commun. 2012; 419 (4): 715–718.

Vacheva A., Ivanova R., Paunova-Krasteva T., Stoitsova S. Released products of pathogenic bacteria stimulate biofilm formation by Escherichia coli K-12 strains. Antonie Van Leeuwenhoek. 2012; 102 (1): 105–119.

Kumari A., Pasini P., Deo S. K., Flomenhoft D., Shashidhar H., Daunert S. Biosensing systems for the detection of bacterial quorum signaling molecules. Anal. Chem. 2006; 78 (22): 7603–7609.

Kumari A., Pasini P., Deo S.K., Flomenhoft D., Shashidhar H., Daunert S. Biosensing systems for the detection of bacterial quorum signaling molecules. Anal. Chem. 2006; 78 (22): 7603–7609.

Vakhitov T.Ya., Protasov E. A., Visnol'd N. V., Tolparov Yu. T., Petrov L. N. Isolation and identification of growth stimulators of Escherichia coli M-17. Zh. Mikrobiol. Epidemiol. Immunobiol. 2003; 2: 7–12.

Vakhitov Tia., Protasov E.A., Visnol'd N.V., Tolparov Iu.T., Petrov L.N. Isolation and identification of growth stimulators of Escherichia coli M-17. Zh. Mikrobiol. Epidemiol. Immunobiol. 2003; 2: 7–12.

Gromova O.A., Torshin I.Yu., Grishina T.R., Garas'ko E.V. Molecular Mechanisms of metabolic effects of prebiotic Hilak Fort intestinal biofloru and exchange of vitamins. Russian Union Medical Professions. Zhurnal Gastro = Russian Union Medical Professions. Gastro Journal. 2013;1:11–16.

Torshin I.Yu., Gromova O.A. 25 mgnovenii molekulyarnoi farmakologii [25 Moments of Molecular Pharmacology]. Moscow, A-Grif, 2012. 678 p.

Joshi-Tope G., Gillespie M., Vastrik I., D'Eustachio P., Schmidt E., de Bono B., Jassal B., Gopinath G. R., Wu G., Matthews L., Lewis S., Birney E., Stein L. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 2005; 33: 428–432.

Joshi-Tope G., Gillespie M., Vastrik I., D'Eustachio P., Schmidt E., de Bono B., Jassal B., Gopinath G.R., Wu G., Matthews L., Lewis S., Birney E., Stein L. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 2005; 33: 428–432.

Gromova O.A., Torshin I.Yu., Volkov A.Yu., Lisitsa A.V., Garas'ko E.V. Molecular mechanisms of the metabolic effects of prebiotics on the survival of the positive microflora. Lechashchii vrach = Practicing doctor. 2013;6:79–83.

Bentley R., Meganathan R. Biosynthesis of vitamin K (menaquinone) in bacteria. Microbiol. Rev. 1982; 46 (3): 241–280.

Reid G., Howard J., Gan B. S. Can bacterial interference prevent infection? Trends Microbiol. 2001; 9 (9): 424–428.

Reid G., Howard J., Gan B.S. Can bacterial interference prevent infection? Trends Microbiol. 2001; 9 (9): 424–428.

Aihara K., Kajimoto O., Hirata H., Takahashi R., Nakamura Y. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J. Am. Coll. Nutr. 2005; 24 (4): 257–265.

Schlegel A., Bohm A., Lee S. J., Peist R., Decker K., Boos W. Network regulation of the Escherichia coli maltose system. J. Mol. Microbiol. Biotechnol. 2002; 4 (3): 301–307.

Schlegel A., Bohm A., Lee S.J., Peist R., Decker K., Boos W. Network regulation of the Escherichia coli maltose system. J. Mol. Microbiol. Biotechnol. 2002; 4 (3): 301–307.

Bochner B. R., Gadzinski P., Panomitros E. Phenotype micro-arrays for high-throughput phenotypic testing and assay of gene function. Genome Res. 2001; 11 (7): 1246–1255.

Bochner B.R., Gadzinski P., Panomitros E. Phenotype microarrays for high-throughput phenotypic testing and assay of gene function. Genome Res. 2001; 11 (7): 1246–1255.

Khavkin A.I. Mikroflora pishchevaritel'nogo takta [Microflora of the Digestive System]. Moscow, FSP, 2012. 424 p.

Florkiewicz H., Szurska G. Role of the Hylak forte preparation in the prevention of dysbacteriosis following intraoral antibiotic therapy. Pol. Tyg. Lek. 1963;18:1066–1068.

Florkiewicz H., Szurska G. Role of the Hylak forte preparation in the prevention of dysbacteriosis following intraoral antibiotic therapy. Pol. Tyg. Lek. 1963; 18: 1066–1068.

Agafonova N.A., Yakovenko E.P., Ivanov A.N., Yakovenko A.V., Pryanishnikova A.S. Features of treatment of patients with post-infectious irritable bowel syndrome. Farmateka = Pharmateca. 2011;15:50–55.

Burkov S.G., Makukh E.A. Irritable bowel syndrome in outpatient practice. Farmateka = Pharmateca. 2009;8:60–64.

Burkov S.G., Makukh E.A. Irritable bowel syndrome in outpatient practice. Farmateka = Pharmateca. 2009; 8: 60–64.

Ardatskaya M.D. Pre- and probiotics correction microecological bowel disorders. Farmateka = Pharmateca. 2011;12:62–68.

Ardatskaya M.D. Pre- and probiotics correction microecological bowel disorders. Farmateka = Pharmateca. 2011; 12: 62–68.

Khavkin A.I. Microflora and development of the immune system. Detskaya gastroenterologiya = Pediatric gastroenterology. 2010;4(3):34–37.

Khavkin A.I. Microflora and development of the immune system. Detskaya gastroenterologiya = Pediatric gastroenterology. 2010; 4 (3): 34–37.

Ploskireva A.A., Usenko D.V., Gorelov A.V. Adaptogenic properties metabolite prebiotic Hilak forte. Infektsionnye bolezni = Infectious diseases. 2010;8(1):48–54.

Ploskireva A.A., Usenko D.V., Gorelov A.V. Adaptogenic properties metabolite prebiotic Hilak forte. Infektsionnye bolezni = Infectious diseases. 2010; 8 (1): 48–54.

Gracheva N.M., Malyshev N.A., Leont'eva N.I., Kondrakova O.A., Partin O.S., Solov'eva A.I., Zatevalov A.M., Koshkina N.K. Restoring metabolite status of intestinal microflora in patients with chronic diseases of the gastrointestinal tract. Infektsionnye bolezni = Infectious diseases. 2006;4(2):37–41.

Rudkowski Z., Bromirska J. Reduction of the duration of salmonella excretion in infants with Hylak forte. Padiatr. Padol. 1991; 26 (2): 111–114.

Gracheva N.M., Partin O.S., Leont'eva N.I., Shcherbakov I.T., Solov'eva A.I. Application of modern prebiotic Hilak forte in the treatment of patients with acute intestinal infections and chronic diseases of the gastrointestinal tract with symptoms of intestinal dysbiosis Epidemiologiya i infektsionnye bolezni = Epidemiology and infectious diseases. 2003;5:32.

The authors declare that there are no conflicts of interest present.